Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brainsway ( (BWAY) ) has issued an update.
On February 18, 2026, BrainsWay highlighted a policy change by Cigna Group’s Evernorth Behavioral Health, which will eliminate prior authorization requirements for transcranial magnetic stimulation coverage for contracted providers, effective March 6, 2026. The move applies to patients covered under Evernorth and Cigna Healthcare plans across 12 states.
BrainsWay’s leadership said the shift should expand timely access to Deep TMS for adolescents and adults with major depressive disorder and patients with obsessive-compulsive disorder who often have not responded to medications or psychotherapy. The company expects the streamlined reimbursement environment to reduce administrative barriers for providers, reinforcing BrainsWay’s competitive position in the U.S. TMS market and supporting broader utilization of its systems.
The most recent analyst rating on (BWAY) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
The score is driven primarily by improved profitability, strong cash generation, and a low-leverage balance sheet, reinforced by raised guidance and strong Q3 operating momentum. These positives are tempered by a demanding P/E valuation and technically stretched momentum signals that raise near-term pullback risk.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a medical technology company specializing in advanced noninvasive neurostimulation treatments for mental health disorders. Using its proprietary Deep Transcranial Magnetic Stimulation platform and H-coil technology, the company offers FDA-cleared therapies for major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with operations in the U.S. and Israel and a focus on expanding clinical adoption and access.
Average Trading Volume: 90,799
Technical Sentiment Signal: Buy
Current Market Cap: $453.7M
See more data about BWAY stock on TipRanks’ Stock Analysis page.